Statistics on Biotechnology Use  
Results by fields of operation
Business Sector Biotechnology indicators by company size. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total 2021;
No. of companies carrying out R&D in Biotechnology;1.226;122;1.348;
%Companies according to biotechnology used: Genetic code;30,5;36;31;
%Companies according to biotechnology used: Functional units;37,6;46,7;38,4;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;20,5;33,6;21,7;
%Companies according to biotechnology used: Bioprocesses;48,6;68,1;50,3;
%Companies according to biotechnology used: Sub-cellular organisms;7,2;18;8,2;
%Companies according to biotechnology used: Bio-computing;24;25,4;24,1;
%Companies according to biotechnology used: Nanobiotechnology;11,8;11,5;11,8;
%Companies according to biotechnology used: Other;17;10,7;16,4;
Companies in which biotechnology activities are: Main and/or exclusive;639;22;661;
Companies in which biotechnology activities are: A secondary line of business;166;22;188;
Companies in which biotechnology activities are: A tool necessary for production;421;78;500;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45,8;45,9;45,8;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;15,6;11,5;15,3;
%Company by field(s) of ultimate application of biotechnology use: Food products;31,5;32;31,5;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24,1;19,6;23,7;
%Company by field(s) of ultimate application of biotechnology use: Environment;16;11,5;15,5;
%Company by field(s) of ultimate application of biotechnology use: Industry;13,4;13,1;13,4;
Personnel in R&D in biotechnology (no. of persons);10.473;5.271;15.744;
Personnel in R&D in biotechnology (no. of persons): Research personnel;5.914;2.465;8.380;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;4.558;2.806;7.364;
Personnel in R&D in biotechnology (no. of persons). Women;5.482;3.242;8.725;
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;3.094;1.426;4.521;
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;2.388;1.816;4.204;
Personnel in R&D in biotechnology (FTE);7.354,4;4.168,8;11.523,2;
Personnel in R&D in biotechnology (FTE): Research personnel;4.402,9;1.938,6;6.341,6;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;2.951,5;2.230,1;5.181,6;
Personnel in R&D in biotechnology (FTE). Women;3.909,3;2.643,4;6.552,7;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;2.305,8;1.158,6;3.464,4;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;1.603,5;1.484,8;3.088,3;
Internal expenditure on R&D (thousands of euros);648.976;388.911;1.037.887;
1) By nature of the expense: Current expenses;577.758;361.713;939.471;
1.1) Remuneration to research personnel;213.250;108.275;321.525;
1.2) Remuneration to technical and auxiliary personnel;104.359;90.297;194.656;
1.3) Other current expenses;260.148;163.141;423.290;
2) By nature of the expense: Capital expenses;71.218;27.197;98.416;
2.1) Land and buildings;8.904;1.246;10.150;
2.2) Equipment and instruments;48.703;23.835;72.538;
2.3) Acquisition of specific R&D software;3.749;1.963;5.713;
2.4) Otros productos de propiedad intelectual específicos para I+D;9.862;153;10.015;
1.1) By origin of the funds: Own funds;428.118;282.919;711.037;
1.2) By origin of the funds: From companies;87.264;34.331;121.595;
1.3) By origin of the funds: Public Administration funds;81.113;26.309;107.422;
1.4) By origin of the funds: From Universities;192;0;192;
1.5) By origin of the funds: From non profit private institutions;1.543;9.213;10.756;
1.6) By origin of the funds: Foreign funds;50.745;36.139;86.884;
Purchase of R&D services in biotechnology (thousands of euros);77.001;68.440;145.440;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;54.755;41.115;95.870;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;22.246;27.324;49.570;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;41,6;21,3;39,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12,5;12,3;12,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;18,8;14,8;18,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;10,9;14,8;11,2;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;15,9;12,3;15,6;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17;11,5;16,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16,3;13,9;16,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;40,8;32,8;40;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;54,9;43,4;53,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21,7;18,8;21,5;
% Companies with income of an international origin related to biotechnological activities;22,8;16,4;22,2;
% Turnover representing income of an international origin related to biotechnological activities;9,1;0,8;1,9;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;57,9;78;65,5;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;42,1;22;34,5;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;93,7;74,2;86,3;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;5,2;23,6;12,2;
% Income of an international origin related with activities according to the classification: Operating source abroad;0,5;2,1;1,1;
% Income of an international origin related with activities according to the classification: Other;0,6;0;0,4;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute